R
Rob Seitz
Researcher at Stanford University
Publications - 7
Citations - 672
Rob Seitz is an academic researcher from Stanford University. The author has contributed to research in topics: Cytokeratin & Breast cancer. The author has an hindex of 4, co-authored 7 publications receiving 662 citations.
Papers
More filters
Journal ArticleDOI
Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome
Matt van de Rijn,Charles M. Perou,Robert Tibshirani,Phillippe Haas,Olli Kallioniemi,Juha Kononen,Joachim Torhorst,Guido Sauter,Markus Zuber,O.R. Köchli,Frank Mross,Holger Dieterich,Rob Seitz,Doug Ross,David Botstein,Patrick O. Brown +15 more
TL;DR: Results of immunohistochemistry studies using monoclonal antibodies against these markers to analyze more than 600 paraffin-embedded breast tumors in tissue microarrays found that expression of cytokeratin 17 and/or cytokersatin 5/6 in tumor cells was associated with a poor clinical outcome.
Patent
Basal cell markers in breast cancer and uses thereof
David Botstein,Patrick O. Brown,Charles M. Perou,Brian Ring,Douglas Ross,Rob Seitz,Jan Matthijs van de Rijn +6 more
TL;DR: In this article, the authors used microarray technology to identify genes whose expression profile across a large group of tumor samples correlates with that of cytokeratin 5/6 and/or 17 markers for basal cells of the normal mammary lactation gland.
Patent
Bstp-trans protein and related reagents and methods of use thereof
TL;DR: In this article, a protein (BSTP-TRANS) and polynucleotides are used to identify and encode BSTPTRANS, which are then used to diagnose and/or predict breast cancer.
Patent
Methods of classifying, diagnosing, stratifying and treating cancer patients and their tumors
David Botstein,Patrick O. Brown,Charles M. Perou,Brian Ring,Douglas Ross,Rob Seitz,Jan Matthijs van de Rijn +6 more
TL;DR: In this article, the authors used microarray technology to identify genes whose expression profile across a large group of tumor samples correlates with that of cytokeratin 5/6 and/or 17 markers for basal cells of the normal mammary lactation gland.
Journal ArticleDOI
Clinical Activity of Pembrolizumab in a Patient With Metastatic Triple-Negative Breast Cancer Without Tumor Programmed Death-Ligand 1 Expression: A Case Report and Correlative Biomarker Analysis
Sajjad Bhatti,Jaimie Heldstab,Carolyn Lehn,Ossama Tawfik,Ryan M. Ash,David R. Hout,Rob Seitz,Daniel B. Bailey,Anne O'Dea,Roy A. Jensen,Fang Fan,Qamar J. Khan,Andrew K. Godwin,Priyanka Sharma +13 more